Epstein-Barr Virus (EBV) Early-Antigen Serologic Testing in Conjunction with Peripheral Blood EBV DNA Load as a Marker for Risk of Posttransplantation Lymphoproliferative Disease

Journal of Infectious Diseases

Volumn 188, Issue 12, 2003, Pages 1853-1864

  Carpentier, Linda ^a   Tapiero, Bruce ^a   Alvarez, Fernando ^a   Viau, Carole ^a   Alfieri, Caroline ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BIOLOGICAL MARKER; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BLOOD; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE MARKER; EPSTEIN BARR VIRUS; EVALUATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; PEDIATRICS; PRIORITY JOURNAL; RISK ASSESSMENT; SEROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SEROLOGIC TESTS; VIRAL LOAD;

EID: 0347320476     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379834     Document Type: Article

References (59)

1. Basgoz N, Preiksaitis JK. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am 1995; 9:901-23.
2. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991; 70:137-60.
3. Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 1993; 99:265-76.
4. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39:461-72.
5. List AF, Greco FA, Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 1987; 5:1673-89.
6. Preiksaitis JK, Cockfield SM. Epstein-Barr virus and lymphoproliferative disorders after transplantation. In: Bowden RA, Ljungman P, Paya CV, eds. Transplant infections. Philadelphia: Lippincott-Raven Publishers, 1998:245-63.
7. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133:173-92.
8. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation: interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62:370-5.
9. Penn I. The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol 1998; 20:343-55.
10. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97:14-24.
11. Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997; 2:33-40.
12. Lucas KG, Pollok KE, Emanuel DJ. Post-transplant EBV induced lymphoproliferative disorders. Leuk Lymphoma 1997; 25:1-8.
13. Swinnen LJ. Overview of posttransplant B-cell lymphoproliferative disorders. Semin Oncol 1999; 26:21-5.
14. Chadburn A, Cesarman E, Knowles DM. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 1997; 14:15-26.
15. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152:876-86.
16. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20:1346-53.
17. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14:214-21.
18. Zangwill SD, Hsu DT, Kichuk MR, et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 1998; 17:1161-6.
19. Finn L, Reyes J, Bueno J, Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998; 22:299-309.
20. Mañez R, Breinig MK, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462-7.
21. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64:1438-42.
22. Boyle GJ, Michaels MG, Webber SA, et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997; 131:309-13.
23. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45:719-27.
24. Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999; 67:990-8.
25. Randhawa PS, Demetris AJ, Pietrzak B, Nalesnik M. Histopathology of renal posttransplant lymphoproliferation: comparison with rejection using the Banff schema. Am J Kidney Dis 1996; 28:578-84.
26. Randhawa PS, Magnone M, Jordan M, Shapiro R, Demetris AJ, Nalesnik M. Renal allograft involvement by Epstein-Barr virus associated post-transplant lymphoproliferative disease. Am J Surg Pathol 1996; 20:563-71.
27. Rosendale B, Yousem SA. Discrimination of Epstein-Barr virus-related posttransplant lymphoproliferations from acute rejection in lung allograft recipients. Arch Pathol Lab Med 1995; 119:418-23.
28. Savoie A, Perpête C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83:2715-22.
29. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84:972-84.
30. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91:3654-61.
31. Allen U, Hébert D, Petric M, et al. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clin Infect Dis 2001; 33:145-50.
32. Gärtner BC, Schäfer H, Marggraff K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002; 40:351-8.
33. Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med 1985; 102:1-7.
34. Strauss SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985; 102:7-16.
35. Pedneault L, Katz BZ, Miller G. Detection of Epstein-Barr virus in the brain by the polymerase chain reaction. Ann Neurol 1992; 32:184-92.
36. Scharf SJ, Horn GT, Erlich HA. Direct cloning and sequence analysis of enzymatically amplified genomic sequences. Science 1986; 233:1076-9.
37. Henle W, Henle G, Niederman JC, Klemola E, Haltia K. Antibodies to early antigens induced by Epstein-Barr virus in infectious mononucleosis. J Infect Dis 1971; 124:58-67.
38. Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV) associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 1973; 11:499-520.
39. Henle G, Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 1966; 91:1248-56.
40. Medeiros LJ. Intermediate and high-grade diffuse non-Hodgkin's lymphomas in the working formulation. In: Sarkin Jaffe E, ed. Surgical pathology of the lymph nodes and related organs. 2nd ed. Major problems in pathology, vol. 16. Philadelphia: WB Saunders, 1995:302-43.
41. Deschler DG, Osorio R, Ascher NL, Lee KC. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. Arch Otolaryngol Head Neck Surg 1995; 121:1037-41.
42. Tanner JE, Alfieri C. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease. Leuk Lymphoma 1996; 21:379-90.
43. Walz G, Zanker B, Melton LB, Suthanthiran M, Strom TB. Possible association of the immunosuppressive and B cell lymphoma-promoting properties of cyclosporine. Transplantation 1990; 49:191-4.
44. Wilkinson AH, Smith JL, Hunsicker LG, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47:293-6.
45. Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999; 68:997-1003.
46. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59:524-9.
47. Cacciarelli TV, Green M, Jaffe R, et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1998; 66: 1047-52.
48. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23:1473-6.
49. Alfieri C, Tanner J, Carpentier L, et al. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood 1996; 87:812-7.
50. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323:1723-8.
51. Canfield CW, Hudnall SD, Colonna JO, et al. Fulminant Epstein-Barr virus-associated post-transplant lymphoproliferative disorders following OKT3 therapy. Clin Transplant 1992; 6:1-9.
52. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Transplantation 1993; 56:88-96.
53. Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JLC. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993; 81:1393-403.
54. Henle W, Henle G. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res 1981; 41:4222-5.
55. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152:876-86.
56. Marker SC, Ascher NL, Kalis JM, Simmons RL, Najarian JS, Balfour HH. Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients. Surgery 1979; 85:433-40.
57. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DLJ. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992; 166:986-94.
58. Sokal EM, Caragiozoglou T, Lamy M, Reding R, Otte JB. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993; 56:1394-8.
59. Rogers BB, Conlin C, Timmons CF, Dawson B, Krisher K, Andrews WS. Epstein-Barr virus PCR correlated with viral histology and serology in pediatric liver transplant patients. Pediatr Pathol Lab Med 1997; 17:391-400.